Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive OV329 in adults with drug-resistant focal epilepsy
NL-OMON61503Phase 2Not yet recruiting
- Sponsor
- Ovid Therapeutics
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Focal Onset Epilepsy comparing OV329 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoints: Incidence, severity, and temporal profile of treatment-emergent adverse events, Clinically significant abnormalities in safety assessments and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
OV329
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on NL-OMON61503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61503.